`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`PFIZER, INC. and
`SAMSUNG BIOEPIS CO., LTD.,1
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner,
`____________
`
`IPR2017-01488
`Patent No. 6,407,213
`____________
`
`PETITIONER PFIZER’S UPDATED MANDATORY NOTICES
`
`1 Samsung Bioepis Co., Ltd.’s IPR2017-02139 has been joined with this
`
`proceeding. (IPR2017-02139, Paper 42.)
`
`
`
`IPR2017-01488
`Petitioner Pfizer’s Updated Mandatory Notices
`
`
`In accordance with 37 C.F.R. §§ 42.8(a)(3) and (b)(2), Petitioner Pfizer
`
`hereby submits the following updated mandatory notices:
`
`A.
`
`37 C.F.R. § 42.8(b)(2): Related Matters
`
`Petitioner concurrently filed an IPR petition for claims of U.S. Patent No.
`
`6,407,213 (IPR2017-01488).
`
`The ’213 patent is the subject of two earlier IPR proceedings filed by third-
`
`party Mylan Pharmaceuticals Inc.: IPR2016–01693 and IPR2016–01694. These
`
`proceedings were terminated by the Board on March 10, 2017 after the parties filed
`
`a Joint Motion to Terminate. Paper No. 24, IPR2016–01693; Paper No. 23,
`
`IPR2016–01694 (March 10, 2017). The ’213 patent is also the subject of two other
`
`earlier IPR proceedings filed by third-party Boehringer Ingelheim Pharmaceuticals,
`
`Inc.: IPR2017-02031 and IPR2017-02032. These proceedings were terminated by
`
`the Board on July 31, 2018 pursuant to a request for adverse judgment by the
`
`Petitioner in those cases.
`
`The ’213 patent is also the subject of IPR2017-01373, IPR2017-01374,
`
`IPR2017-02139, and IPR2017-02140. Petitioner is not a party to those proceedings.
`
`The ’213 patent is also at issue in Genentech, Inc. et al. v. Amgen Inc., No. 1-
`
`17-cv-01407 (D. Del.); Genentech, Inc. et al. v. Amgen Inc., No. 1-17-cv-01471 (D.
`
`Del.); Celltrion, Inc. et al. v. Genentech, Inc. et al., No. 4-18-cv-00274 (N.D. Cal.);
`
`Celltrion Inc. et al. v. Genentech, Inc. et al. No. 2018-2160 (Fed. Cir.); Genentech,
`
`1
`
`
`
`
`IPR2017-01488
`Petitioner Pfizer’s Updated Mandatory Notices
`
`Inc. et al. v. Celltrion, Inc. et al., No. 1-18-cv-00095 (D. Del.); Genentech, Inc. et
`
`al. v. Amgen, Inc., No. 1-18-cv-00924 (D. Del.); Genentech, Inc. et al. v. Samsung
`
`Bioepis Co., Ltd., No. 1-18-cv-01363 (D. Del.); and Genentech, Inc. et al. v.
`
`Celltrion, Inc. et al., No. 1-18-cv-01025 (D. Del.). Petitioner is not a party to these
`
`proceedings.
`
`Patent Owner has asserted the ’213 patent against Petitioner in Genentech,
`
`Inc. v. Pfizer, Inc., No. 1-17-cv-01672 (D. Del.), filed November 17, 2017.
`
`Petitioner is not aware of any other judicial or administrative matters that
`
`would affect, or be affected by, a decision in the proceeding.
`
`Date: September 25, 2018
`
`Respectfully submitted,
`
` /Amanda Hollis/
`Amanda Hollis (Reg. No. 55,629)
`Attorney For Petitioner Pfizer, Inc.
`
`2
`
`
`
`IPR2017-01488
`Petitioner Pfizer’s Updated Mandatory Notices
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a copy of the foregoing Updated
`
`Notices was served on September 25, 2018, via electronic service on lead and
`
`back-up counsel:
`
`For Genentech, Inc.
`david.cavanaugh@wilmerhale.com
`lauren.blakely@wilmerhale.com
`robert.gunther@wilmerhale.com
`abrausa@durietangri.com
`ddurie@durietangri.com
`andrew.danford@wilmerhale.com
`kevin.prussia@wilmerhale.com
`lisa.pirozzolo@wilmerhale.com
`
`For Samsung Bioepis Co., Ltd.:
`ddrivas@whitecase.com
`sweingaertner@whitecase.com
`eric.majchrzak@whitecase.com
`athakore@whitecase.com
`
` /Amanda Hollis/
`Amanda Hollis
`
`4
`
`